Burning Rock's Pivot: A High-Stakes Bet on China's In-Hospital Future

GUANGZHOU, China – September 10, 2026 – Burning Rock Biotech Limited, a key player in China's precision oncology landscape, today presented a complex picture of a company in deep transition. Its second-quarter financial results reveal a firm grappling with short-term financial headwinds, including a 9.3% year-over-year revenue decline to RMB134.7 million (US$19.9 million) and a near-doubling of its net loss to RMB18.4 million (US$2.7 million). Yet, beneath these headline figures lies a deliberate and high-stakes strategic pivot, one that is steering the company away from its traditional laboratory services and directly into the heart of China’s hospital system, all while its product pipeline gains critical momentum with national regulators.

While the year-over-year numbers suggest strain, the company emphasized a sequential recovery from a difficult first quarter. “After navigating a challenging first quarter, we delivered the anticipated sequential recovery in the second quarter,” stated Yusheng Han, Chairman and CEO of Burning Rock. This recovery is underpinned by a fundamental restructuring of its business model, a gambit that is proving costly in the near term but which management believes is essential for sustainable growth.

A Regulatory Tailwind

The most significant bright spot in Burning Rock’s report is its substantial progress within China's stringent regulatory framework. The company announced that three of its key next-generation sequencing (NGS) diagnostic kits have entered expedited review channels with the National Medical Products Administration (NMPA). This is a crucial development in a country where the standard approval process for complex Class III medical devices can stretch for 24 to 36 months.

By securing entry into the NMPA's 'Priority Review Channel' and 'Special Review Procedure for Innovative Medical Devices,' Burning Rock could see its time-to-market dramatically reduced. These so-called "Green Channels" are designed to accelerate the approval of innovative and clinically urgent technologies, potentially cutting review times down to a matter of months. For Burning Rock, this includes its OncoScreen® BCMatch Tissue Kit, which is now on track to become China's first approved NGS-based companion diagnostic for breast cancer. Furthermore, its CanCatch Custom Kits for minimal residual disease (MRD) monitoring have been admitted to the Special Review Procedure, a first for a WES-based personalized MRD platform in China. The OncoCompass Target liquid biopsy kit was also accepted for priority review.

This regulatory momentum is the foundation of the company's long-term strategy. Mr. Han noted, “With several products having entered the Priority Review Channel and Special Review Procedure for Innovative Medical Devices of CMDE and new registration certificates expected in the coming quarters, we are confident that we will achieve sustainable and meaningful top-line growth over the long term.” Successful and timely approvals would not only validate the company's technology but also provide the commercial products needed to fuel its new business model.

The In-Hospital Gambit

The financial turbulence is a direct consequence of Burning Rock's strategic shift from a centralized laboratory model to an in-hospital service model. The company is actively helping hospitals establish their own in-house NGS testing platforms, selling them the necessary kits and equipment. The Q2 results illustrate this transition starkly: revenue from the in-hospital business grew a healthy 7.4% to RMB67.1 million, driven by increased sales volume. Simultaneously, revenue from the legacy central laboratory business fell by 10.0%, and pharma research and development services cratered by 31.8%.

This pivot is a calculated response to the evolving Chinese healthcare market, which is moving towards greater standardization and compliance in advanced diagnostics. By embedding its technology within hospitals—of which it now partners with 94—Burning Rock aims to create a stickier, more scalable revenue stream. The improved gross margin for the in-hospital segment, which rose to 77.1% from 74.4% a year prior, suggests the underlying economics of this model are favorable. However, the transition phase is creating a significant drag on overall performance as established revenue lines decline faster than the new one can grow.

Recalibrating the Financial Engine

The strategic shift is also reflected in the company's operating expenses. Research and development spending was cut dramatically, falling 37.3% to RMB31.2 million. This may not signal a retreat from innovation but rather a tactical reallocation of resources. With several products now in the final stages of regulatory review, the company appears to be shifting its focus from early-stage research to development and commercialization readiness.

In contrast, selling and marketing expenses climbed 22.7%, and general and administrative expenses rose 19.2%. This increased spending is the necessary fuel for the in-hospital push, as the company invests in building out its sales force and support infrastructure to service a growing network of hospital partners. The challenge for Burning Rock is to manage this period of inverted investment, where R&D is scaled back to fund a commercial expansion that has yet to fully pay off.

This recalibration has come at a cost to the bottom line. The net loss of RMB18.4 million for the quarter is a significant concern, especially when viewed against the company's cash reserves of RMB419.1 million (US$61.8 million). While this provides a runway, the current burn rate underscores the urgency for its pipeline products to gain approval and begin generating revenue.

A Barometer for China's Oncology Market

Burning Rock's journey serves as a compelling case study for the broader Chinese precision oncology sector. The NGS market in China is booming, projected to grow from just under US$1 billion in 2026 to nearly US$1.9 billion by 2031. The company's current revenue dip, running counter to this powerful market trend, highlights the immense internal and external pressures facing firms in this space. Navigating a complex business model transition while contending with fierce domestic competition and a demanding regulatory environment is a formidable task.

The company’s success or failure in this pivot will be a closely watched barometer. It will test whether a strategy focused on regulatory compliance and deep integration with the state-run hospital system can ultimately triumph, even if it requires weathering significant financial storms along the way.